Extended Data Table 2 Participant disposition and analysis sets

From: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

  1. Twelve participants per dose cohort received the priming and the booster doses, except for two participants who did not receive the booster dose owing to a study-drug-unrelated withdrawal by one participant (1-μg dose level), and concurrent nasopharyngitis not related to the study drug in another participant (10-μg dose level). Safety analysis: numbers of participants for whom one week of reactogenicity follow-up after both doses was evaluable at data cut-off. Antibody analysis: numbers of participants for whom virus neutralization assays and S1- and RBD-binding IgG assays were performed. T cell analysis: numbers of participants for whom IFNγ ELISpot and flow cytometry (in parentheses) data were available at data cut-off.
  2. The + sign after the days of injection indicates the follow-up period of at least seven days. N/A, not applicable. *8 and **7 for CD4+ T cell responses.
Back to article page